moneyheap
QGEN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is QIAGEN N.V. (QGEN) stock moving?
QGEN is trading as a deal-pinned stock. The closing price has stayed between $50.07 and $50.97 over the last 30 sessions, with a $50.51 close on Nov 10. Volume spiked to 40.8M shares on Oct 22, the first session in the window, and has since run at roughly 3-7M shares a day. The business combination agreement with Crown NL Bidco (EQT-linked, dated Oct 21) is the dominant factor, and the 6-K excerpt does not show the offer price, so the spread to the eventual price cannot be measured. Q3 results were mixed: adjusted EPS of $0.65 matched estimates, but sales of $548M missed the $573.3M consensus, and management suspended 2026 guidance while the offer is pending. One headline describes revenue as beating outlook, which conflicts with the sales miss. Barclays cut its rating to Equal Weight and its target to $53 on Oct 28, about 5% above the current price. The Parse Biosciences partnership and the Pratt board approval are minor. Brodsky & Smith's investigation notice is routine. Overall, the news flow is negative on fundamentals and guidance, but the stock's price is tied to deal completion rather than operating results.
News behind the analysis
- QIAGEN Reports Q3 2026 Financial Results and Suspends Guidance Amid EQT OfferQIAGEN reported Q3 2026 results and suspended its 2026 financial guidance while the EQT Private Equity acquisition offer remains pending. One headline describes Q3 revenue as beating outlook, which conflicts with the Benzinga sales figure.
- Qiagen Q3 Adj. EPS $0.65, Inline, Sales $548.000M Miss $573.331M EstimateAdjusted EPS of $0.65 matched expectations, while sales of $548M fell short of the $573.3M consensus estimate.
- QIAGEN Shareholders Approve Appointment of Jonathan M. Pratt to Managing BoardShareholders approved Jonathan M. Pratt as a Managing Director and member of the Managing Board. This is a routine governance step.
- QIAGEN N.V. Files Form 6-K for Third Quarter 2026QIAGEN filed its Form 6-K with the SEC for the quarter ended September 30, 2026, furnishing the Q3 results as Exhibit 99.1.
- Parse Biosciences and Nomic Bio Announce Partnership for Immune Biology DatasetParse Biosciences, a QIAGEN company, partnered with Nomic Bio to build 'Cascade,' a 100-million-cell foundational dataset for immune biology research. The deal is small relative to the company's valuation.
- Brodsky & Smith Investigates Proposed Acquisition of QIAGEN N.V.The law firm Brodsky & Smith announced an investigation into the proposed acquisition of QIAGEN by EQT Private Equity. Such shareholder-notice releases are common and carry little new information.
- Barclays Downgrades QIAGEN to Equal WeightBarclays cut QIAGEN from Overweight to Equal Weight and lowered its price target from $55 to $53.
- Barclays Downgrades Qiagen to Equal-Weight, Lowers Price Target to $53Barclays moved Qiagen to Equal-Weight and set a $53 price target. The target is about 5% above the latest close of $50.51.
- Business Combination Agreement between Crown NL Bidco B.V. and QIAGEN N.V. (Project Quail), Exhibit 99.3 to Form 6-KQIAGEN filed a business combination agreement dated October 21, 2026 with Crown NL Bidco B.V. covering an offer for the company, with conditions, financing, and termination terms. The offer price is not shown in the provided excerpt.
About QIAGEN N.V.
QIAGEN is a Netherlands-based company that makes the kits, instruments and software labs use to extract and test DNA and RNA, serving both research labs and hospitals and clinical labs. Its best-known products include sample-preparation kits, the QuantiFERON blood test for latent tuberculosis, QIAcuity digital PCR, QIAstat-Dx syndromic testing and bioinformatics software. In October 2026 it agreed to be acquired by EQT Private Equity through a tender offer, and it has suspended its 2026 outlook while the deal is pending.
How it makes money
Most revenue comes from consumables such as reagent kits and test cartridges that labs reorder over and over, plus sales of the instruments those kits run on and bioinformatics software licenses. Annual sales are roughly $2 billion. The largest single product line is QuantiFERON TB testing, at about $500 million in 2025. The rest comes from sample-technology kits, digital PCR, syndromic testing and QIAGEN Digital Insights software. Customers are split between diagnostic labs and life-science research or pharma buyers.
What usually moves QGEN
- Progress and terms of the pending EQT takeover
- QuantiFERON TB testing demand, including immigration screening
- Spending by academic and pharma research labs
- Currency moves (euro vs. US dollar)
- New product launches and regulatory approvals